These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31697947)

  • 1. Exploring Chemical Space for New Substances to Stabilize a Therapeutic Monoclonal Antibody.
    Tosstorff A; Menzen T; Winter G
    J Pharm Sci; 2020 Jan; 109(1):301-307. PubMed ID: 31697947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studying Excipient Modulated Physical Stability and Viscosity of Monoclonal Antibody Formulations Using Small-Angle Scattering.
    Xu AY; Castellanos MM; Mattison K; Krueger S; Curtis JE
    Mol Pharm; 2019 Oct; 16(10):4319-4338. PubMed ID: 31487466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidating the weak protein-protein interaction mechanisms behind the liquid-liquid phase separation of a mAb solution by different types of additives.
    Wu G; Wang S; Tian Z; Zhang N; Sheng H; Dai W; Qian F
    Eur J Pharm Biopharm; 2017 Nov; 120():1-8. PubMed ID: 28754261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities.
    Whitaker N; Xiong J; Pace SE; Kumar V; Middaugh CR; Joshi SB; Volkin DB
    J Pharm Sci; 2017 Nov; 106(11):3230-3241. PubMed ID: 28668340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-drug conjugates- stability and formulation.
    Duerr C; Friess W
    Eur J Pharm Biopharm; 2019 Jun; 139():168-176. PubMed ID: 30940541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
    Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
    J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Excipient Effects on Reversible Self-Association, Backbone Flexibility, and Solution Properties of an IgG1 Monoclonal Antibody at High Concentrations: Part 1.
    Hu Y; Arora J; Joshi SB; Esfandiary R; Middaugh CR; Weis DD; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):340-352. PubMed ID: 31201906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of Electrostatic Mediated Antibody Liquid-Liquid Phase Separation by Charged and Noncharged Preferentially Excluded Excipients.
    Banks DD; Cordia JF
    Mol Pharm; 2021 Mar; 18(3):1285-1292. PubMed ID: 33555888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations.
    Garidel P; Pevestorf B; Bahrenburg S
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):125-39. PubMed ID: 26455339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational Characterization of Antibody-Excipient Interactions for Rational Excipient Selection Using the Site Identification by Ligand Competitive Saturation-Biologics Approach.
    Jo S; Xu A; Curtis JE; Somani S; MacKerell AD
    Mol Pharm; 2020 Nov; 17(11):4323-4333. PubMed ID: 32965126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ionic strength and pH on the physical and chemical stability of a monoclonal antibody antigen-binding fragment.
    Wang T; Kumru OS; Yi L; Wang YJ; Zhang J; Kim JH; Joshi SB; Middaugh CR; Volkin DB
    J Pharm Sci; 2013 Aug; 102(8):2520-37. PubMed ID: 23824562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of High Throughput Screening Techniques to Predict Stability of Monoclonal Antibody Formulations During Early Stage Development.
    Goldberg DS; Lewus RA; Esfandiary R; Farkas DC; Mody N; Day KJ; Mallik P; Tracka MB; Sealey SK; Samra HS
    J Pharm Sci; 2017 Aug; 106(8):1971-1977. PubMed ID: 28456733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brij-58, a potential injectable protein-stabilizer used in therapeutic protein formulation.
    Yue L; Yan Z; Li H; Liu X; Sun P
    Eur J Pharm Biopharm; 2020 Jan; 146():73-83. PubMed ID: 31811896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Hydrogen Exchange Mass Spectrometry as a Stability-Indicating Method for Formulation Excipient Screening for an IgG4 Monoclonal Antibody.
    Toth RT; Pace SE; Mills BJ; Joshi SB; Esfandiary R; Middaugh CR; Weis DD; Volkin DB
    J Pharm Sci; 2018 Apr; 107(4):1009-1019. PubMed ID: 29269271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of Protein Pharmaceuticals: Recent Advances.
    Manning MC; Holcomb RE; Payne RW; Stillahn JM; Connolly BD; Katayama DS; Liu H; Matsuura JE; Murphy BM; Henry CS; Crommelin DJA
    Pharm Res; 2024 Jul; 41(7):1301-1367. PubMed ID: 38937372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipicolinic acid as a novel spore-inspired excipient for antibody formulation.
    Batalha IL; Ke P; Tejeda-Montes E; Uddin S; van der Walle CF; Christie G
    Int J Pharm; 2017 Jun; 526(1-2):332-338. PubMed ID: 28495581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High throughput thermostability screening of monoclonal antibody formulations.
    He F; Hogan S; Latypov RF; Narhi LO; Razinkov VI
    J Pharm Sci; 2010 Apr; 99(4):1707-20. PubMed ID: 19780136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Small-Scale Process for Predicting Donnan and Volume Exclusion Effects During Ultrafiltration/Diafiltration Process Development.
    Abel J; Kosky A; Ball N; Bacon H; Kaushik R; Kleemann GR
    J Pharm Sci; 2018 May; 107(5):1296-1303. PubMed ID: 29339134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local dynamics and their alteration by excipients modulate the global conformational stability of an lgG1 monoclonal antibody.
    Thakkar SV; Kim JH; Samra HS; Sathish HA; Bishop SM; Joshi SB; Volkin DB; Middaugh CR
    J Pharm Sci; 2012 Dec; 101(12):4444-57. PubMed ID: 23060088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody.
    Cleland JL; Lam X; Kendrick B; Yang J; Yang TH; Overcashier D; Brooks D; Hsu C; Carpenter JF
    J Pharm Sci; 2001 Mar; 90(3):310-21. PubMed ID: 11170024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.